The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 24970841.
- Also identified by DOI 10.1158/1078-0432.CCR-14-0933 and PMC identifier 4184978.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It is conceivable that, in the near future, an assay that defines the likelihood of a patient with advanced cancer to respond to immunotherapy based on PD1/L1 blockade will be the initial decision point to select the treatment of patients with any cancer type.
Medical subject headings
- Neoplasms